Enlicitide decanoate - Merck Sharp & Dohme
Alternative Names: Enlicitide Chloride; MK-0616Latest Information Update: 08 Sep 2025
At a glance
- Originator Merck Sharp & Dohme Corp.
- Class Antihyperlipidaemics; Cyclic peptides; Urologics
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypercholesterolaemia; Hyperlipoproteinaemia type IIa
Most Recent Events
- 02 Sep 2025 Topline efficacy and adverse events data from the phase III CORALreef Lipids trial in Hypercholesterolaemia released by Merck Sharp & Dohme Corp.
- 02 Sep 2025 Merck Sharp & Dohme completes enrolment in the phase III CORALreef Outcomes trial in Hypercholesterolaemia (Treatment-experienced) in USA, Argentina, Australia, Taiwan, Brazil, Canada, China, Chile, Colombia, Denmark, France, Germany, Hong Kong, Hungary, Israel, Italy, Japan, Mexico, Netherlands, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, South Korea, Spain, Turkey, and United Kingdom (PO), prior to September 2025 (NCT06008756)
- 28 Jul 2025 Merck Sharp & Dohme Corp. completes the phase III CORALreef Lipids trial in Hypercholesterolaemia in USA, Argentina, China, Colombia, Germany, Israel, Italy, Japan, Mexico, South Africa, South Korea, Spain, Turkey, and Taiwan (PO) (NCT05952856)